Latest revenue
$2.4M
as of 2025-12-31
Latest net income
$-34.8M
as of 2025-12-31
Net margin
-1462.8%
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ATOS is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $38.3M
- Enterprise value
- $6.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.26×
- Dividend yield
- —
- 52-wk high
- $7.56
- 52-wk low
- $0.53
- Beta
- —
- Shares out
- 8.6M
5-year trend
About ATOS
Business description and risk factors will appear here once ATOS's latest filing is fully ingested.
Profitability
Operating margin
-1562.5%
129.1%Net margin
-1462.8%
132.3%Return on equity
-48.6%
36.3%Return on assets
-73.0%
118.9%Leverage
Debt / equity
-0.33×
580.6%Debt / assets
-50.1%
871.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-9.6M | -42.7% | — |
Q4 2025 2025-12-31 | — | — | $-10.9M | -72.3% | — |
Q3 2025 2025-09-30 | — | — | $-8.7M | -20.2% | — |
Q2 2025 2025-06-30 | — | — | $-8.4M | -39.2% | — |
Q1 2025 2025-03-31 | — | — | $-6.7M | -14.3% | — |
Q4 2024 2024-12-31 | — | — | $-6.3M | — | — |
Q3 2024 2024-09-30 | — | — | $-7.2M | -16.1% | — |
Q2 2024 2024-06-30 | — | — | $-6.0M | +38.5% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ATOS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ATOS
Institutional value
$3.3M
Total shares held
631.7K
Distinct holders
17
-49 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 349.1K | $1.8M | — | New |
| 2 | BlackRock, Inc. | 133.2K | $700.5K | -1.9M (-93.3%) | Trimmed |
| 3 | UBS Group AG | 92.0K | $484.1K | -298.0K (-76.4%) | Trimmed |
| 4 | VANGUARD FIDUCIARY TRUST CO | 52.2K | $274.8K | — | New |
| 5 | Vanguard Global Advisers, LLC | 3.1K | $16.2K | — | New |
| 6 | GROUP ONE TRADING LLC | 609 | $3.2K | -6.1K (-90.9%) | Trimmed |
| 7 | JPMORGAN CHASE & CO | 383 | $1.8K | -37.7K (-99.0%) | Trimmed |
| 8 | WELLS FARGO & COMPANY/MN | 296 | $1.6K | +213 (+256.6%) | Added |
| 9 | SBI Securities Co., Ltd. | 113 | $594 | -1.5K (-92.8%) | Trimmed |
| 10 | TD Waterhouse Canada Inc. | 103 | $525 | -1.5K (-93.4%) | Trimmed |
| 11 | BNP PARIBAS FINANCIAL MARKETS | 98 | $515 | -1.4K (-93.5%) | Trimmed |
| 12 | North Star Investment Management Corp. | 80 | $421 | — | New |
| 13 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 46 | $242 | -454 (-90.8%) | Trimmed |
| 14 | Napier Financial, LLC | 6 | $32 | — | New |
| 15 | Bogart Wealth, LLC | 5 | $26 | — | New |
| 16 | Clearstead Advisors, LLC | 4 | $22 | -66 (-94.3%) | Trimmed |
| 17 | Avion Wealth | 318 | $1 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ATOS's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.